(Q44437005)

English

Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C.

scientific article published in May 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Anna Hollander

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Graham R Foster

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Scandinavian Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

577-585

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group.

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Chronic hepatitis C: updated Swedish consensus

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

The impact of diagnosis of hepatitis C virus on quality of life.

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Standardization of hepatitis C virus RNA quantification

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365520500325952

21 January 2018

Identifiers

10.1080/00365520500325952

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44437005&oldid=1590394535"